Novelix Pharma.

What is the technical trend for Novelix Pharma.?

As of May 27, 2025, Novelix Pharma's technical trend is mildly bullish, supported by positive momentum from the MACD and RSI, although caution is advised due to a mildly bearish KST.

As of 27 May 2025, the technical trend for Novelix Pharma has changed from bullish to mildly bullish. The weekly MACD and RSI are both bullish, indicating positive momentum in the short term. The daily moving averages also reflect a bullish stance. However, the KST on a weekly basis is mildly bearish, suggesting some caution. The Bollinger Bands show a mildly bullish trend weekly and bullish monthly, while the Dow Theory indicates no trend weekly but mildly bullish monthly. Overall, the current stance is mildly bullish, supported by strong monthly indicators and daily moving averages, despite some mixed signals from the KST.

Who are the peers of the Novelix Pharma.?

Novelix Pharma's peers include Khemani Distrib., M K Exim India, MRP Agro, and others, with varying management risks and growth rates. Notably, Novelix Pharma has the highest 1-year return at 138.43%, significantly outperforming its peers.

Peers: The peers of Novelix Pharma are Khemani Distrib., M K Exim India, MRP Agro, Sattva Sukun, Silgo Retail, Purv Flexi, Magson Retail, Osia Hyper Reta., Fonebox Retail, and Cell Point.<BR><BR>Quality Snapshot: Excellent management risk is observed at Khemani Distrib., M K Exim India, MRP Agro, Magson Retail, and Osia Hyper Reta., while Average management risk is found at Cell Point. Below Average management risk is noted for Novelix Pharma., Sattva Sukun, Silgo Retail, Purv Flexi, and Fonebox Retail. Growth is Excellent at M K Exim India and Osia Hyper Reta., Good at MRP Agro and Sattva Sukun, while Below Average growth is seen at Novelix Pharma., Silgo Retail, Purv Flexi, and the rest. Capital Structure is Excellent at Khemani Distrib. and M K Exim India, Good at MRP Agro and Sattva Sukun, while Below Average capital structure is noted for Novelix Pharma., Silgo Retail, Purv Flexi, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Novelix Pharma. at 138.43%, while the lowest is M K Exim India at -4.79%. Novelix Pharma.'s 1-year return significantly outperforms all peers. Additionally, Sattva Sukun, MRP Agro, and Silgo Retail have negative six-month returns.

Who are in the management team of Novelix Pharma.?

As of March 2023, the management team of Novelix Pharma includes Arvind Kumar Bhangadia (Non Executive Director), Natwarlal Ramgopal Modani, Sagar Rajendra Karwa, and Monam Kapoor (all Independent Directors), Aditya Bhangadia (Managing Director), and Ravi Bhangadia (Chairman & Wholetime Director). Each member contributes to the company's strategic direction and governance.

As of March 2023, the management team of Novelix Pharma includes the following individuals:<BR><BR>1. Arvind Kumar Bhangadia - Non Executive Director<BR>2. Natwarlal Ramgopal Modani - Independent Director<BR>3. Sagar Rajendra Karwa - Independent Director<BR>4. Monam Kapoor - Independent Director<BR>5. Aditya Bhangadia - Managing Director<BR>6. Ravi Bhangadia - Chairman & Wholetime Director<BR><BR>Each member plays a significant role in guiding the company's strategic direction and governance.

What does Novelix Pharma. do?

Novelix Pharmaceuticals Ltd is a micro-cap pharmaceutical company that transitioned from finance to drug development after its incorporation in 1994. As of March 2025, it reported net sales of 209 Cr and a net profit of 2 Cr.

Overview: <BR>Novelix Pharmaceuticals Ltd operates in the pharmaceutical and drug industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was incorporated in 1994 under the name Trimurthi Securities Ltd. It initially engaged in finance and investments in securities but ceased operations due to market volatility and voluntarily de-registered as a Non-Banking financial company. Subsequently, it diversified into the pharmaceutical sector. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 209 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 116 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.24 <BR>Return on Equity: -30.14% <BR>Price to Book: 16.72<BR><BR>Contact Details: <BR>Address: 4-4-231/1/2/ABC Inderbagh, Sultan Bazar Hyderabad Telangana : 500095 <BR>Tel: 91-40-24757370 <BR>Email: info@trimurthidrugs.com <BR>Website: http://www.trimurthidrugs.com

Who are the top shareholders of the Novelix Pharma.?

The top shareholders of Novelix Pharma are Srinidhi Fine-chemicals LLP with 38.67%, followed by Mallela Venkatramna Reddy at 11.6%, and individual investors holding 36.84%. There are currently no mutual funds or foreign institutional investors involved.

The top shareholders of Novelix Pharma include Srinidhi Fine-chemicals LLP, which holds the largest stake at 38.67%. The highest public shareholder is Mallela Venkatramna Reddy, who owns 11.6%. Additionally, individual investors collectively hold 36.84% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

How big is Novelix Pharma.?

As of 24th July, Novelix Pharmaceuticals Ltd has a market capitalization of 111.00 Cr and reported Net Sales of 4.40 Cr with a Net Profit loss of 2.17 Cr over the latest four quarters. Shareholder's Funds were 7.40 Cr and Total Assets were 8.67 Cr as of March 2022.

As of 24th July, Novelix Pharmaceuticals Ltd has a market capitalization of 111.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Novelix Pharmaceuticals reported Net Sales of 4.40 Cr. However, the company experienced a Net Profit loss of 2.17 Cr during the same period.<BR><BR>For the latest annual period ending in March 2022, the Shareholder's Funds were recorded at 7.40 Cr, while Total Assets amounted to 8.67 Cr.

Are Novelix Pharma. latest results good or bad?

Novelix Pharmaceuticals reported impressive annual growth with net sales up 3,124.63% to Rs 43.21 crore and a profit after tax increase to Rs 0.29 crore. However, recent quarterly results show slower growth and a significant profit decline, leading analysts to issue a 'Sell' call, indicating mixed overall performance.

Novelix Pharmaceuticals has shown a remarkable improvement in its financial performance for the six months ending June 2025, with net sales reaching Rs 43.21 crore, a staggering year-on-year growth of 3,124.63%. This significant increase indicates a strong upward trend in revenue generation compared to the previous year.<BR><BR>Additionally, the company reported a profit after tax (PAT) of Rs 0.29 crore, up from Rs 0.05 crore in the prior twelve months, reflecting an enhanced profitability alongside its revenue growth.<BR><BR>However, it's important to note that there are some mixed signals in the latest quarterly results. For the quarter ending June 2025, net sales experienced a quarter-on-quarter growth of only 7.14%, which is a decline from the previous quarter's growth of 293.58%. Furthermore, the standalone net profit saw a significant decrease of 38.89% compared to the previous quarter.<BR><BR>Despite the overall positive annual growth figures, MarketsMOJO has issued a 'Sell' call on the stock, indicating some caution among analysts. The company's overall score has improved significantly, from -2 to 9 in the last three months, suggesting a positive shift in its financial standing.<BR><BR>In summary, while Novelix Pharmaceuticals has demonstrated impressive annual growth, the recent quarterly performance raises some concerns, leading to a mixed assessment of its latest results.

Is Novelix Pharma. overvalued or undervalued?

As of November 27, 2025, Novelix Pharma is considered very expensive and overvalued with a PE ratio of 97.12, significantly higher than its peers, despite a strong stock performance of 148.52% over the past year.

As of 27 November 2025, the valuation grade for Novelix Pharma has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 97.12, an EV to EBIT of 70.40, and an EV to EBITDA of 68.28. These ratios are starkly higher than its peers, such as Sun Pharma with a PE of 37.62 and Divi's Lab at 69.34, both categorized as very expensive.<BR><BR>In comparison to its industry peers, Novelix Pharma's valuation metrics suggest it is not only overvalued but also out of sync with more attractively priced competitors like Cipla and Dr Reddy's Labs, which have PE ratios of 22.67 and 18.08, respectively. While Novelix has shown impressive stock performance over the past year with a return of 148.52% compared to the Sensex's 6.84%, this does not justify its current high valuation levels.

How has been the historical performance of Novelix Pharma.?

Novelix Pharma has experienced a declining trend in net sales and profitability, with significant losses reported since March 2020, including a net loss of -2.12 Cr in March 2022. Despite these challenges, the company's cash position improved, indicating some liquidity stability.

Answer:<BR>The historical performance of Novelix Pharma shows a declining trend in net sales and profitability over the past several years, with significant losses reported in recent periods.<BR><BR>Breakdown:<BR>Novelix Pharma's net sales have decreased from 10.50 Cr in March 2018 to 8.61 Cr in March 2022, reflecting a downward trend. The total operating income also followed this decline, dropping from 10.50 Cr in March 2018 to 8.61 Cr in March 2022. The company's total expenditure, excluding depreciation, peaked at 13.04 Cr in March 2021 but fell to 11.18 Cr in March 2022. Operating profit (PBDIT) has consistently been negative since March 2020, with a loss of -2.02 Cr reported in March 2022. Profit before tax and profit after tax also remained negative, with losses of -2.12 Cr and -2.12 Cr, respectively, in March 2022. The company's earnings per share (EPS) worsened from -0.01 in March 2017 to -2.22 in March 2022. Despite these challenges, the company's cash and cash equivalents improved from 0.59 Cr in March 2017 to 2.00 Cr in March 2022, indicating some liquidity stability. Overall, Novelix Pharma's financial performance has shown significant challenges, particularly in revenue generation and profitability, while maintaining a stable cash position.

Should I buy, sell or hold Novelix Pharmaceuticals Ltd?

When is the next results date for Novelix Pharmaceuticals Ltd?

The next results date for Novelix Pharmaceuticals Ltd is 12 February 2026.

The next results date for Novelix Pharmaceuticals Ltd is scheduled for 12 February 2026.

Which are the latest news on Novelix Pharma.?

Why is Novelix Pharmaceuticals Ltd falling/rising?

As of 11-Feb, Novelix Pharmaceuticals Ltd's stock price is at 62.68, down 0.48%. The stock has performed well recently but is currently underperforming its sector and experiencing a significant drop in investor participation.

As of 11-Feb, Novelix Pharmaceuticals Ltd's stock price is currently at 62.68, reflecting a change of -0.3, or a decrease of 0.48%. Despite the recent decline in price, the stock has shown strong performance over the past week and month, with increases of 2.45% and 9.41% respectively. However, it is important to note that today, the stock underperformed its sector by 1.31%. <BR><BR>Additionally, while the stock is trading above its moving averages across various time frames (5-day, 20-day, 50-day, 100-day, and 200-day), there has been a significant drop in investor participation, with delivery volume on 10 February falling by 81.65% compared to the 5-day average. This decline in trading activity may contribute to the downward pressure on the stock price. <BR><BR>Overall, while Novelix Pharmaceuticals Ltd has shown strong historical performance, the current drop in price can be attributed to underperformance relative to its sector and a notable decrease in investor participation.